Review of Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK

Pre-publication Review of

Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK

Reviewed On September 23, 2020

Verified

Submitted to

Reviewed by

Actions

Reviewed on September 23, 2020

Source

References

Kun-Ling, T., Pei-Ling, H., Wan-Ching, C., Hui-Ching, C., Yu-Ting, H., Shih-Hung, C. 2021. Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. Cell & Bioscience.